Premium
Extracorporeal Shock Wave Lithotripsy with the Storz Modulith SL20: the First 500 Patients
Author(s) -
LISTON T. G.,
MONTGOMERY B. S. I.,
BULTITUDE M. I.,
TIPTAFT R. C.
Publication year - 1992
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1992.tb15589.x
Subject(s) - medicine , extracorporeal shock wave lithotripsy , ureter , surgery , lithotripsy , urology , extracorporeal
Summary— Our initial experience of extracorporeal shock wave lithotripsy (ESWL) with the Storz Modulith SL20 is reported. A total of 500 patients with 551 renal and 120 ureteric stones, mean diameter 11.9 mm, underwent 746 treatments; 68.2% of patients required a single treatment. The mean treatment rate for renal calculi was 1.4 and for ureteric calculi it was 1.5, rising to 4.2 for staghorns; 62.2% of treatments were performed on an out‐patient basis. Analgesia (intravenous fentanyl) was required in 60.9% of treatments for renal calculi but in only 38.2% of those for ureteric calculi. The overall stone‐free rate at 3 months was 77.6%, with a further 14.7% of patients having fragments <3 mm in diameter that required no further treatment. The stone‐free rate was dependent on the site of the stone, with the majority of residual fragments lying in a lower pole calix. There were few complications. The Modulith is an efficient and safe lithotripter capable of treating stones in the kidney and throughout the ureter.